2003
DOI: 10.1016/s0960-894x(03)00556-0
|View full text |Cite
|
Sign up to set email alerts
|

Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
69
0

Year Published

2007
2007
2023
2023

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 92 publications
(69 citation statements)
references
References 7 publications
0
69
0
Order By: Relevance
“…The contribution of the efflux pump was judged significant if the inhibitor decreased the MIC of levofloxacin eightfold or greater (17,19).…”
Section: Methodsmentioning
confidence: 99%
“…The contribution of the efflux pump was judged significant if the inhibitor decreased the MIC of levofloxacin eightfold or greater (17,19).…”
Section: Methodsmentioning
confidence: 99%
“…For example, corilagin, 8,9) tellimagrandin I, 9,10) epicatechin gallate, 11) epigallocatechin gallate 12) or many flavonoids 13) potentiated antibacterial activity of b-lactams against methicillin-resistant Staphylococcus aureus (MRSA). Baicalein potentiated activities of tetracycline and b-lactams against MRSA, 14) 5Ј-methoxyhydonocarpin inhibited NorA pump in S. aureus 15) and MC-207,110 (phenylalanine arginine bnaphthylamide, PAbN) and its relatives potentiated some types of antimicrobials that are substrates of one of multidrug efflux pumps, MexAB-OprM of Pseudomonas aeruginosa [16][17][18][19][20][21] or AcrAB-TolC of Escherichia coli 22) and Enterobacter aerogenes. 23) Regarding to VRE, allicin, which potentiated activity of vancomycin against VRE, 24) and [10]gingerol and some detergents, such as sodium dodecyl sulfate (SDS) and Triton X-100, which potentiated some antimicrobials including aminoglycosides against enterococci 25) have been reported.…”
mentioning
confidence: 99%
“…Despite the potential of this combinatorial regimen in APDT, no clinical feasibility studies have yet been performed, mainly due to the biological instability, poor solubility, and in vivo toxicity of some export pump inhibitors [201]. These factors, however, do not rule out the utility of this approach for the treatment of local infections, such as those that cause dental diseases and in superficial skin wounds, where systemic toxicity issues can be avoided.…”
Section: Efflux Pump Inhibitorsmentioning
confidence: 99%